CD4⁺CD25^hiCD127⁻ Treg and CD4⁺CD45R0⁺CD49b⁺LAG3⁺ Tr1 cells in bone marrow and peripheral blood samples from children with neuroblastoma

References

• Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455:930-5; PMID:18724359; http://dx.doi.org/10.1038/nature07261
   PubMed Web of Science ®Google Scholar
• Mosse YP, Laudenslager M, Khazi D, Carlisle AJ, Winter CL, Rappaport E, Maris JM. Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet 2004; 75:727-30; PMID:15338462; http://dx.doi.org/10.1086/424530
   PubMed Web of Science ®Google Scholar
• Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999; 17:2264-79; PMID:10561284; http://dx.doi.org/10.1200/jco.1999.17.7.2264
   PubMed Web of Science ®Google Scholar
• Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol 2015; 33:3008-17; PMID:26304901; http://dx.doi.org/10.1200/JCO.2014.59.4648
   PubMed Web of Science ®Google Scholar
• Morandi F, Corrias MV, Pistoia V. Evaluation of bone marrow as a metastatic site of human neuroblastoma. Ann NY Acad Sci 2015; 1335:23-31; PMID:25315505; http://dx.doi.org/10.1111/nyas.12554
   PubMed Web of Science ®Google Scholar
• Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009; 27:289-97; PMID:19047291; http://dx.doi.org/10.1200/JCO.2008.16.6785
   PubMed Web of Science ®Google Scholar
• Vo KT, Matthay KK, Neuhaus J, London WB, Hero B, Ambros PF, Nakagawara A, Miniati D, Wheeler K, Pearson AD et al. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. J Clin Oncol 2014; 32:3169-76; PMID:25154816; http://dx.doi.org/10.1200/JCO.2014.56.1621
   PubMed Web of Science ®Google Scholar
• Roychoudhuri R, Eil RL, Restifo NP. The interplay of effector and regulatory T cells in cancer. Curr Opin Immunol 2015; 33:101-11; PMID:25728990; http://dx.doi.org/10.1016/j.coi.2015.02.003
   PubMed Web of Science ®Google Scholar
• Gowda M, Godder K, Kmieciak M, Worschech A, Ascierto ML, Wang E, Marincola FM, Manjili MH. Distinct signatures of the immune responses in low risk versus high risk neuroblastoma. J Transl Med 2011; 9:170; PMID:21978632; http://dx.doi.org/10.1186/1479-5876-9-170
   PubMed Web of Science ®Google Scholar
• Morandi F, Croce M, Cangemi G, Barco S, Rigo V, Carlini B, Amoroso L, Pistoia V, Ferrini S, Corrias MV. IL-10 and ARG-1 concentrations in bone marrow and peripheral blood of metastatic neuroblastoma patients do not associate with clinical outcome. J Immunol Res 2015; 2015:718975; PMID:25961062; http://dx.doi.org/10.1155/2015/718975
   PubMed Web of Science ®Google Scholar
• Tilak T, Sherawat S, Agarwala S, Gupta R, Vishnubhatla S, Bakhshi S. Circulating T-regulatory cells in neuroblastoma: a pilot prospective study. Pediatr Hematol Oncol 2014; 31:717-22; PMID:24684178; http://dx.doi.org/10.3109/08880018.2014.886002
   PubMed Web of Science ®Google Scholar
• Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389:737-42; PMID:9338786; http://dx.doi.org/10.1038/39614
   PubMed Web of Science ®Google Scholar
• Battaglia M, Gregori S, Bacchetta R, Roncarolo MG. Tr1 cells: from discovery to their clinical application. Semin Immunol 2006; 18:120-7; PMID:16464609; http://dx.doi.org/10.1016/j.smim.2006.01.007
   PubMed Web of Science ®Google Scholar
• Gregori S, Goudy KS, Roncarolo MG. The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory T cells. Front Immunol 2012; 3:30; PMID:22566914; http://dx.doi.org/10.3389/fimmu.2012.00030
   PubMed Web of Science ®Google Scholar
• Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006; 212:28-50; PMID:16903904; http://dx.doi.org/10.1111/j.0105-2896.2006.00420.x
   PubMed Web of Science ®Google Scholar
• Gagliani N, Magnani CF, Huber S, Gianolini ME, Pala M, Licona-Limon P, Guo B, Herbert DR, Bulfone A, Trentini F et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med 2013; 19:739-46; PMID:23624599; http://dx.doi.org/10.1038/nm.3179
   PubMed Web of Science ®Google Scholar
• Chen J, Chen Z. The effect of immune microenvironment on the progression and prognosis of colorectal cancer. Med Oncol 2014; 31:82; PMID:25034363; http://dx.doi.org/10.1007/s12032-014-0082-9
   PubMed Web of Science ®Google Scholar
• Vicente D, Podesta M, Pitto A, Pozzi S, Lucchetti S, Lamparelli T, Tedone E, Ibatici A, Figari O, Frassoni F et al. Progenitor cells trapped in marrow filters can reduce GvHD and transplant mortality. Bone Marrow Transplant 2006; 38:111-7; PMID:16751783; http://dx.doi.org/10.1038/sj.bmt.1705413
   PubMed Web of Science ®Google Scholar
• Zhao E, Wang L, Dai J, Kryczek I, Wei S, Vatan L, Altuwaijri S, Sparwasser T, Wang G, Keller ET et al. Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer. Oncoimmunology 2012; 1:152-61; PMID:22720236; http://dx.doi.org/10.4161/onci.1.2.18480
   PubMed Web of Science ®Google Scholar
• Brinkrolf P, Landmeier S, Altvater B, Chen C, Pscherer S, Rosemann A, Ranft A, Dirksen U, Juergens H, Rossig C. A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease. Int J Cancer 2009; 125:879-86; PMID:19480009; http://dx.doi.org/10.1002/ijc.24461
   PubMed Web of Science ®Google Scholar
• Zou L, Barnett B, Safah H, Larussa VF, Evdemon-Hogan M, Mottram P, Wei S, David O, Curiel TJ, Zou W. Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res 2004; 64:8451-5; http://dx.doi.org/10.1158/0008-5472.CAN-04-1987
   PubMed Web of Science ®Google Scholar
• Scaruffi P, Morandi F, Gallo F, Stigliani S, Parodi S, Moretti S, Bonassi S, Fardin P, Garaventa A, Zanazzo G et al. Bone marrow of neuroblastoma patients shows downregulation of CXCL12 expression and presence of IFN signature. Pediatr Blood Cancer 2012; 59:44-51; PMID:21994039; http://dx.doi.org/10.1002/pbc.23339
   PubMed Web of Science ®Google Scholar
• Baecher-Allan C, Anderson DE. Regulatory cells and human cancer. Semin Cancer Biol 2006; 16:98-105; PMID:16378733; http://dx.doi.org/10.1016/j.semcancer.2005.11.003
   PubMed Web of Science ®Google Scholar
• Menetrier-Caux C, Gobert M, Caux C. Differences in tumor regulatory T-cell localization and activation status impact patient outcome. Cancer Res 2009; 69:7895-8; PMID:19808962; http://dx.doi.org/10.1158/0008-5472.CAN-09-1642
   PubMed Web of Science ®Google Scholar